rs121909547 — SERPINC1 Arg79Cys

Pathogenic missense variant in the antithrombin III heparin-binding domain; heterozygous carriers have antithrombin deficiency conferring an approximately 14-fold increased risk of venous thromboembolism

See your personal result for SERPINC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

Antithrombin III Arg79Cys — A High-Penetrance Clotting Barrier Breach

Antithrombin III — encoded by SERPINC1 — is the body's primary brake on the coagulation cascade. It neutralizes thrombin and activated Factor Xa, directly blocking the two central enzymes that form fibrin clot. When antithrombin works at full capacity, a runaway clotting reaction cannot occur. The Arg79Cys variant destroys part of that brake. Carriers produce antithrombin protein with a crippled heparin-binding domain, and the crippled protein cannot do its job — the coagulation system runs hotter and clots more readily. The result is one of the strongest known inherited thrombophilias, with a risk of venous thromboembolism (VTE) estimated at 14-fold above the general population11 estimated at 14-fold above the general population
Croles et al., 2018 Bayesian meta-analysis of 19 studies, Semin Thromb Hemost.

The Mechanism

The SERPINC1 gene is on the minus strand of chromosome 1 (position 173,914,726 on GRCh38). The Arg79Cys variant arises from a CpG dinucleotide hotspot22 CpG dinucleotide hotspot
CpG sites are hypermutable because cytosine methylation spontaneously deaminates to thymine; recurrent independent mutations at the same codon are common in antithrombin deficiency in exon 2 of SERPINC1, where a G-to-A change on the plus strand converts arginine at position 79 to cysteine in the mature protein. Arginine-79 is located in the [heparin-binding domain | The N-terminal region of antithrombin that physically contacts heparan sulfate proteoglycans on endothelial cells, dramatically accelerating the inhibitory rate constant] near the N-terminus of the protein. Arginine's positively charged guanidinium group makes electrostatic contact with negatively charged heparin; cysteine, with its uncharged thiol, cannot replicate this interaction. The result is a [Type II heparin-binding site (HBS) deficiency | The WHO classifies antithrombin deficiency into Type I (quantitative: low antigen and activity) and Type II (qualitative: normal antigen, reduced activity). Arg79Cys is a Type II HBS variant]: the protein is present in normal amounts but cannot bind heparin at full affinity, impairing the 1,000-fold rate acceleration that heparin normally provides to the inhibitory reaction.

Heterozygous carriers have functional antithrombin activity typically around 50-75% of normal — enough to prevent spontaneous thrombosis in many circumstances, but not enough to withstand strong provoking stimuli: surgery, pregnancy, immobility, estrogen exposure, or concurrent thrombophilic variants.

The Evidence

The evidence base for antithrombin deficiency and VTE is among the most robust in inherited thrombophilia. A Bayesian meta-analysis of 19 studies by Croles and colleagues33 Bayesian meta-analysis of 19 studies by Croles and colleagues
2018, Seminars in Thrombosis and Hemostasis calculated a pooled OR of 14.0 (95% credible interval 5.5-29.0) for first VTE in antithrombin-deficient individuals. Annual VTE incidence was 1.2% in deficient individuals versus 0.07% in the general population — a 17-fold difference in absolute rates. After a first VTE, annual recurrence without anticoagulation reached 8.8% versus 4.3% in non-deficient patients.

A separate meta-analysis by Di Minno et al.44 meta-analysis by Di Minno et al.
13 studies, 3,452 VTE cases; Thrombosis Research 2015 confirmed an OR of 16.26 (95% CI 9.90-26.70), making antithrombin deficiency substantially stronger than either Factor V Leiden (OR ~5-7) or prothrombin G20210A (OR ~3-5).

A nuance relevant to rs121909547 specifically: because Arg79Cys is a Type II HBS mutation, it may carry somewhat lower risk than Type I (quantitative) deficiency. A retrospective cohort of 540 SERPINC1 mutation carriers by Alhenc-Gelas et al.55 retrospective cohort of 540 SERPINC1 mutation carriers by Alhenc-Gelas et al.
Thrombosis and Haemostasis 2017 found that Type II HBS mutations had an adjusted relative risk of 0.28 compared to Type I mutations — still representing a substantial absolute VTE risk, but a meaningful gradient worth knowing for clinical counseling. Even at the lower end of the antithrombin deficiency risk spectrum, the absolute VTE risk substantially exceeds that of Factor V Leiden or prothrombin G20210A.

Practical Actions

The clinical management of antithrombin deficiency centers on three domains. First, thromboprophylaxis during high-risk periods: surgery, hospitalization, prolonged immobility, and pregnancy each require active management. Second, contraception and hormonal therapy: estrogen-containing hormonal contraceptives are generally avoided because estrogen is itself prothrombotic and the combination multiplies risk dramatically. Third, anticoagulation after any VTE event: given the high recurrence rate (8.8%/year without anticoagulation), extended or indefinite anticoagulation is typically recommended after a first unprovoked VTE.

Antithrombin concentrate (plasma-derived or recombinant) is available for acute thrombosis or high-risk situations (peri-surgical, peri-partum) in deficient individuals when standard anticoagulation is insufficient. This is a specialist-level intervention, but carriers should know it exists.

Hematology referral for formal thrombophilia evaluation is recommended for all carriers.

Interactions

The most clinically important interactions are additive with other prothrombotic states. A carrier of rs121909547 who also carries Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963) has independent defects in both coagulation inhibition and coagulation factor overproduction — a multiplicative risk combination. Acquired prothrombotic conditions (antiphospholipid syndrome, myeloproliferative neoplasms, cancer, nephrotic syndrome) also compound with antithrombin deficiency in a clinically significant way.

During pregnancy, antithrombin levels physiologically decline by 20-30% in the third trimester, which means a carrier starts closer to the critical threshold for thrombosis and falls below it more easily. Antithrombin concentrate is sometimes used peripartum in this setting.

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-carrier Normal

Normal antithrombin function — no SERPINC1 Arg79Cys thrombophilia

You carry two copies of the reference G allele at rs121909547. Your SERPINC1 gene produces antithrombin III with an intact heparin-binding domain, providing full anticoagulant protection. This is the common genotype found in over 99.99% of the population. You do not carry the Arg79Cys antithrombin deficiency variant.

AG AT Deficiency Carrier High Risk

One copy of Arg79Cys — antithrombin III deficiency with approximately 14-fold elevated VTE risk

Antithrombin III, produced by SERPINC1, is the primary inhibitor of thrombin (Factor IIa) and Factor Xa in the coagulation cascade. Normally, antithrombin's N-terminal heparin-binding domain anchors it to heparan sulfate on endothelial cell surfaces, dramatically accelerating its inhibitory rate. The Arg79Cys substitution replaces a positively charged arginine (critical for electrostatic heparin contact) with an uncharged cysteine, substantially reducing heparin affinity.

This is classified as a Type II heparin-binding site (HBS) deficiency: your antithrombin antigen level is typically normal (distinguishing it from Type I deficiency), but functional activity measured by heparin cofactor assays is reduced. Functional activity in heterozygous carriers typically ranges from 50-80% of normal.

Key risk contexts: - Surgery and hospitalization: The combination of immobility, tissue injury, and inflammatory coagulation activation with reduced antithrombin protection makes the perioperative period highest-risk. - Pregnancy and postpartum: Antithrombin levels normally fall 20-30% in late pregnancy, pushing carriers further below the protective threshold. The postpartum period is the single highest-risk window for VTE in antithrombin-deficient women. - Estrogen-containing contraceptives: Estrogen upregulates coagulation factors while simultaneously suppressing natural anticoagulants including antithrombin. The interaction with an already-deficient antithrombin system is multiplicative for VTE risk. - Recurrent VTE: After a first VTE, annual recurrence without anticoagulation is estimated at 8.8%, more than double the 4.3% recurrence rate in non-deficient patients.

AA AT Deficiency Homozygous High Risk

Two copies of Arg79Cys — homozygous antithrombin deficiency, extremely rare and very high thrombosis risk

Homozygous type II HBS antithrombin deficiency is extraordinarily rare. Most antithrombin deficiency homozygotes in the literature carry type I null mutations and present with severe neonatal thrombosis. Type II HBS homozygotes may have a milder phenotype than type I homozygotes because some residual antithrombin function is retained, but the clinical course is still severe compared to heterozygous carriers.

If confirmed, management requires immediate hematology consultation for: - Assessment of residual functional antithrombin activity - Decision on long-term anticoagulation strategy - Antithrombin concentrate availability planning - Genetic counseling for family members